Potential for combined modality therapy of cyclooxygenase inhibitors and radiation

Progress in Experimental Tumor Research

Volumn 37, Issue , 2003, Pages 193-209

  Saha, Debabrata ^a   Choy, Hak ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; DRUG DERIVATIVE; ISOENZYME; MEMBRANE PROTEIN; PACLITAXEL; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; RADIOSENSITIZING AGENT; TAXOID;

ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHYSIOLOGY; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MEMBRANE PROTEINS; NEOPLASMS; PACLITAXEL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RADIATION-SENSITIZING AGENTS; TAXOIDS;

EID: 0042632588     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071374     Document Type: Article

References (49)

1. Fornace AJ Jr: Mammalian genes induced by radiation: Activation of genes associated with growth control. Annu Rev Genet 1992;26:507-526.
2. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 1994;266:1821-1828.
3. Riley PA: Free radicals in biology: Oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994;65:27-33.
4. McKenna WG, Bernhard EJ, Markiewicz DA, Rudoltz MS, Maity A, Muschel RJ: Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: Influence of H-ras on the G2 delay. Oncogene 1996;12:237-245.
5. Morgan SE, Kastan MB: p53 and ATM: Cell cycle, cell death, and cancer. Adv Cancer Res 1997;71:1-25.
6. Williams CS, Mann M, DuBois RN: The role of cyclooxygenases in inflammation, cancer and development. Oncogene 1999;18:7908-7916.
7. 2 formation (2). N Engl J Med 1988;319:761-767.
8. Oates JA, Brash A, Fitzgerald G: Comparison of the effects of selective inhibition of thromboxane synthase with those of inhibition of the cyclooxygenase enzyme in man. Trans Am Clin Climatol Assoc 1983;95:157-162.
9. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
10. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT: COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000;89:2637-2645.
11. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T: Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764.
12. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-2011.
13. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T: Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005.
14. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
15. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
16. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ: Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998;280:1268-1270.
17. Crew TE, Elder DJ, Paraskeva C: A cyclooxygenase-2 (COX-2)-selective non-steroidal antiinflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: Regulation of COX-2 by butyrate. Carcinogenesis 2000;21:69-77.
18. Elder DJ, Halton DE, Crew TE, Paraskeva C: Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000;86:553-560.
19. Elder DJ, Halton DE, Hague A, Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679-1683.
20. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-11403.
21. Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245-4249.
22. Masferrer JL, Koki A, Seibert K: COX-2 inhibitors. A new class of antiangiogenic agents. Ann NY Acad Sci 1999;889:84-86.
23. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
24. Seed MP, Brown JR, Freemantle CN, Papworth JL, Colville-Nash PR, Willis D, Somerville KW, Asculai S, Willoughby DA: The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 1997;57:1625-1629.
25. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-2259.
26. Tsuji S, Tsujii M, Kawano S, Hori M: Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. J Exp Clin Cancer Res 2001;20:117-129.
27. Goodwin JS, Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295-315.
28. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
29. 2 in human colon cancer cells. Cancer Res 1998;58:362-366.
30. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ: Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18649-18657.
31. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, Ng EK, Chung SC, Sung JJ: Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001;84:335-339.
32. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-867.
33. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M: Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001;49:1213-1217.
34. Steinauer KK, Gibbs I, Ning S, French JN, Armstrong J, Knox SJ: Radiation induces upregulation of cyclooxygenase-2 protein in PC-3 cells. Int J Radiat Oncol Biol Phys 2000;48:325-328.
35. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ: Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999;91:1501-1504.
36. Furuta Y, Hunter N, Barkley T Jr, Hall E, Milas L: Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 1988;48:3008-3013.
37. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-1365.
38. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-1331.
39. Withers HR, Elkind MM: Radiosensitivity and fractionation response of crypt cells of mouse jejunum. Radiat Res 1969;38:598-613.
40. Stone HB: Leg contracture in mice: An assay of normal tissue response. Int J Radiat Oncol Biol Phys 1984;10:1053-1061.
41. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ: Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000;6:2513-2520.
42. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, DuBois RN: A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001;7:2998-3005.
43. Gallo O: Re: Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 2000;92:346-347.
44. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594.
45. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59: 3374-3378.
46. Kakeji Y, Maehara Y, Ikebe M, Teicher BA: Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys 1997;37:1115-1123.
47. Dicker AP, Williams TL, Grant DS: Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 2001;24:438-442.
48. Hawkey CJ: COX-2 inhibitors. Lancet 1999;353:307-314.
49. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 2000;40:124-132.